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Various psychiatric disorders such as major depression are associated with abnormalities in
emotional processing. Evidence indicating involvement of the endocannabinoid system in
emotional processing, and thus potentially in related abnormalities, is increasing. In the
present study, we examined the role of the endocannabinoid system in processing of stimuli
with a positive and negative emotional content in healthy volunteers. A pharmacological
functional magnetic resonance imaging (fMRI) study was conducted with a placebo-controlled,
cross-over design, investigating effects of the endocannabinoid agonist Δ9-tetrahydrocannabi-
nol (THC) on brain function related to emotional processing in 11 healthy subjects. Performance
and brain activity during matching of stimuli with a negative (‘fearful faces’) or a positive
content (‘happy faces’) were assessed after placebo and THC administration. After THC
administration, performance accuracy was decreased for stimuli with a negative but not for
stimuli with a positive emotional content. Our task activated a network of brain regions
including amygdala, orbital frontal gyrus, hippocampus, parietal gyrus, prefrontal cortex, and
regions in the occipital cortex. THC interacted with emotional content, as activity in this
network was reduced for negative content, while activity for positive content was increased.
These results indicate that THC administration reduces the negative bias in emotional
processing. This adds human evidence to support the hypothesis that the endocannabinoid
system is involved in modulation of emotional processing. Our ﬁndings also suggest a possibleElsevier B.V. and ECNP. All rights reserved.
o.2013.06.009
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M.G. Bossong et al.1688role for the endocannabinoid system in abnormal emotional processing, and may thus be
relevant for psychiatric disorders such as major depression.
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Accurate processing of emotional information is an essential
aspect of appropriate social interactions and interpersonal
relationships. Abnormalities in emotional processing are
among the most important characteristics of psychiatric
disorders such as major depression, bipolar disorder and
schizophrenia, with signiﬁcant consequences for social
functioning and subjective well-being of patients
(Leppanen, 2006; Phillips et al., 2008). Evidence is accu-
mulating for involvement of the endocannabinoid (eCB)
system in emotional processing (Lafenetre et al., 2007).
Additionally, a possible role for the eCB system in abnorm-
alities in emotional processing related to psychiatric dis-
orders has been suggested (Ashton and Moore, 2011; Hill
et al., 2009).
The eCB system is a retrograde messenger system that
regulates both excitatory and inhibitory neurotransmission,
and consists of cannabinoid receptors and accompanying
endogenous ligands (Heifets and Castillo, 2009). Modulation
of the eCB system changes emotional responses and proces-
sing of emotional information. In humans, for example,
smoking cannabis can produce a euphoriant effect, with
feelings of intoxication and decreased anxiety, alertness and
tension (Ashton, 2001). Administration of Δ9-tetrahydrocan-
nabinol (THC), the main psychoactive component in cannabis
and partial agonist of the cannabinoid CB1 receptor, has been
shown to reduce perception of fearful facial emotions in
healthy volunteers (Ballard et al., 2012), whereas both acute
and long-term administration of the eCB antagonist rimona-
bant appear to induce a bias away from positive emotions on
a memory recognition task (Horder et al., 2009, 2012). In
animals, low doses of cannabinoid agonists or drugs that
enhance levels of endogenous cannabinoids reduce anxiety-
like behavior (Kathuria et al., 2003; Marco et al., 2004;
Valjent et al., 2002; see for a review Hill et al. (2009)), while
disruption of eCB-mediated synaptic regulation produces
anxiety- or depressive-like states (Griebel et al., 2005;
Martin et al., 2002; see for a review Lafenetre et al. (2007)).
Cannabinoid receptors are highly expressed in many of
the key regions for emotional processing (Herkenham et al.,
1991; Katona et al., 2001), such as the occipital and
temporal lobes, which are involved in perceptual emotional
processing, the amygdala and orbital frontal cortex, which
are involved in emotion recognition and generation of
emotional reactions (LeDoux, 2003), and the anterior
cingulate and prefrontal cortex, which are involved in
regulation of emotional reactions (Adolphs, 2002; Phillips
et al., 2008). Based on this widespread involvement, the
purpose of the present study was to examine network-wide
interaction effects of the eCB system with emotional
content of stimuli. For this purpose, we conducted a
pharmacological functional MRI (fMRI) study with healthy
volunteers, measuring the effects of THC administration onbrain function related to stimuli with either a negative
(‘fearful faces’) or positive (‘happy faces’) emotional
content.
So far, the role of the eCB system in human emotional
processing has been investigated in a limited number of
functional neuroimaging studies with administration of THC
(Fusar-Poli et al., 2009; Phan et al., 2008). Speciﬁcally
examining the effects of THC in the amygdala region with an
identical task as used in the present study, Phan et al.
(2008) found reduced amygdala reactivity for processing of
stimuli with a negative emotional content. Fusar-Poli et al.
(2009) reported less consistent effects, as THC increa-
sed activity in precuneus and primary motor cortex, and
reduced activity in bilateral middle frontal gyrus and
posterior cingulate cortex during a gender discrimination
task with stimuli with a negative emotional content.
On the basis of recent neural models, we expected that
processing of emotional stimuli would activate a wide
network of brain regions, including amygdala, orbital fron-
tal gyrus, prefrontal cortex, anterior cingulate cortex, and
temporal and occipital lobes (Adolphs, 2002; Phillips et al.,
2008). Based on both the study of Phan et al. (2008), in
which a similar design was used as in the present study, as
well as on the reported alterations in processing of emo-
tional information after administration of cannabinoids
(Ballard et al., 2012; Horder et al., 2009; Horder et al.,
2012), it was hypothesized that THC would reduce the
negative bias in emotional processing, and shift it towards
a positive bias. We expected this to be reﬂected in reduced
brain activity after THC administration when stimuli with a
negative emotional content are processed, and increased
activity after THC administration when stimuli with a
positive emotional content are processed.
2. Experimental procedures
This study is part of the Pharmacological Imaging of the Cannabinoid
System (PhICS) project, the design and objectives of which are
provided in a methodological paper (van Hell et al., 2011).
2.1. Subjects
Fourteen healthy male right-handed subjects were recruited
through ﬂyers, posters and internet advertisements. All subjects
used cannabis on an incidental basis, deﬁned as having used
cannabis at least four times but at most once a week in the year
before inclusion in the study. All subjects were in good physical
health as assessed by medical history and physical examination, and
were screened for axis I psychiatric disorders using the Dutch
version of the Mini International Neuropsychiatric Interview for
DSM-IV clinical disorders. Subjects were asked to refrain from
cannabis for at least two weeks before the ﬁrst study day until
study completion. Illicit drug use other than cannabis was not
allowed within six months prior to inclusion. Compliance was tested
by means of a urine sample at the beginning of each test day. For
further details on inclusion and exclusion criteria we refer to van
Table 1 Subject characteristics (n=11).
Characteristic Mean7SD Range
Age (years) 21.572.5 18–26
IQ 105.275.5 98–113
Height (cm) 183.476.5 175–195
Weight (kg) 74.177.6 65–87
BMI (kg/m2) 22.071.2 20.1–
23.6
Cannabis use (Occasions/year) 20.079.4 4–30
Tobacco smoking (Cigarettes/
week)
0.370.7 0–2
Alcohol consumption (Units/
week)
12.075.9 5–20
Coffee consumption (Units/week) 12.7711.6 0–35
Illicit drug use (Occasions
lifetime)
1.071.8 0–5
Use of cannabis, tobacco, alcohol and coffee was given for
the year before inclusion in the study. Subjects refrained
from cannabis for at least two weeks before the ﬁrst study
day until study completion and from alcohol for 48 h before
each study day. Caffeine intake and smoking were not
allowed from the moment of arrival until the end of a study
day. Illicit drug use other than cannabis was at least more
than 6 months before the ﬁrst study day. All subjects showed
negative urine screening at both study days.
1689Endocannabinoid system in emotional processingHell et al. (2011). All volunteers gave written informed consent
before entry into the study. The study was approved by the
Independent Ethics Committee of the University Medical Center
Utrecht, the Netherlands, in accordance to the Declaration of
Helsinki 2008.
Results are reported on 11 out of the 14 included subjects. One
subject did not complete the study procedure due to a strong
disruptive response to inhalation of medication during one of the
scanning sessions. Two other subjects were excluded because of an
absence of elevated THC plasma levels and movement-related
errors during scanning, respectively. Subject characteristics are
summarized in Table 1.
2.2. Design and procedure
In a double-blind, randomized, placebo-controlled, crossover
pharmacological fMRI study, subjects underwent two scanning
sessions after administration of placebo and of THC. Study days
were scheduled at least 2 weeks apart to allow for complete
clearance of drugs. Two weeks before the ﬁrst study day,
participants were familiarized with the scanner environment
using a mock scanner.
On the beginning of each study day, a catheter was placed
intravenously in the left arm for the withdrawal of blood samples.
Subsequently, subjects performed three cognitive paradigms, dur-
ing which functional MRI scans were obtained. One of these
paradigms was the emotional processing task. Paradigm sequence
was randomized between subjects, but remained unchanged within
subjects across sessions. Results of other assessments are reported
elsewhere (Bossong et al., 2012a; Bossong et al., 2012b; van Hell
et al., 2011). Although there is some overlap in subjects participat-
ing in our current and previous studies, none of the published
studies have identical experimental groups.
On study days, subjects received subsequent doses of THC or
placebo with 30 min intervals. Drugs were administered before each
fMRI task using a Volcanos vaporizer (Storz–Bickel GmbH, Tuttlingen,Germany) according to a method described earlier (Bossong et al.,
2009; Zuurman et al., 2008). The ﬁrst THC dose was 6 mg, followed
by three doses of 1 mg each to maintain stable levels of CNS effects.
See van Hell et al. (2011) for detailed study procedures.
2.3. Drug levels and behavioral measurements
Venous blood samples were collected to determine plasma con-
centrations of THC and its two most important metabolites, 11-OH-
THC and 11-nor-9-carboxy-THC, and were processed according to
Zuurman et al. (2008). Subjective effects were determined with
two sets of visual analog scales (Bond and Lader, 1974; Bowdle
et al., 1998), which were performed consecutively at baseline
and before and after task performance, and analyzed as described
previously (Bossong et al., 2009). Heart rate was monitored
continuously during scanning (van Buuren et al., 2009). VAS data
and heart rate were corrected for baseline values, and analyzed
with repeated measures MANOVA (factors drug and time) and a
paired t test, respectively.
2.4. Task paradigm
Emotional processing was assessed with an emotional faces task
consisting of two conditions involving processing of facial expres-
sions of emotion (fearful (‘FF’) and happy faces (‘HF’), respec-
tively) and a sensorimotor control condition (‘CT’) (Figure 1) (Hariri
et al., 2002; Phan et al., 2008). During FF and HF, subjects viewed a
trio of unfamiliar faces and selected one of the two bottom faces
that expressed the same facial emotion as the target face on top.
The target and congruent probe face displayed either a fearful or
happy expression, while the incongruent probe face displayed a
neutral expression. The identity of all three faces was always
different. FF and HF were interspersed with a sensorimotor control
condition in which subjects viewed a trio of simple geometric
shapes (circles, vertical and horizontal ellipses) and selected one of
the two bottom shapes identical to the target shape on top.
Subjects responded by pressing one of two buttons with their
right thumb.
The emotional faces task consisted of 17 experimental blocks of
24 s: four each for FF and HF, interleaved with nine control blocks,
for a total task length of 7 min. The order of blocks was counter-
balanced. All blocks were preceded by a 4 s instruction (in Dutch):
“Match Faces” or “Match Shapes”, followed by four different trios
of images presented sequentially for 5 s each, randomized for all
conditions. Trios of faces were balanced for gender. All facial
images were derived from a standard set of pictures of facial affect
(Ekman and Friesen, 1976).
Outcome measures included reaction time for correct responses
and the mean percentage of correctly identiﬁed targets. Group
differences in reaction time and performance accuracy between
placebo and THC were analyzed using repeated measures MANOVA
with drug (two levels: placebo and THC) and condition (two levels:
FF and HF) as factors. Post hoc paired t tests were performed to
further investigate effects of THC on individual task conditions.
2.5. Image acquisition
Image acquisition was performed on a Philips Achieva 3.0 T scanner
(Philips Medical Systems, Best, the Netherlands). Functional images
were obtained using a 3D PRESTO-SENSE pulse sequence (Neggers
et al., 2008) (parameters: scan time 0.6075 s; TR 22.5 ms (in
contrast to EPI, for PRESTO the TR is much shorter than the time
to scan one volume, see Neggers et al., 2008); TE 33.2 ms; ﬂip
angle=101; FOV 224 256 160; matrix 56 64 40; voxel size
4 mm isotropic; 40 slices (sagittal orientation); 700 volumes). A
high-contrast volume with a ﬂip angle 271 was scanned for
Table 2 Subjective effects of Δ9-tetrahydrocannabinol (THC) (n=11).
Assessment Drug effect (F(1,10)) Mean placebo score (7SD) Mean THC score (7SD)
VAS feeling high 11.06, p=0.008n 1.1474.79 34.77732.76
VAS internal perception 6.21, p=0.032n 0.3271.06 5.1476.86
VAS external perception 11.97, p=0.006n 0.6872.25 10.2377.93
VAS alertness 8.19, p=0.017n 5.6373.80 18.86714.30
VAS contentedness 6.96, p=0.025n 2.3676.19 9.73710.38
VAS calmness 7.72, p=0.020n 5.11710.90 11.25720.23
VAS anxiety 3.60, p=0.087nn 1.5973.92 7.50713.69
Statistical analysis was performed with baseline corrected values using repeated measures ANOVA with drug and time as factors. VAS,
Visual Analogue Scale.
nSigniﬁcant difference (po0.05).
nnTrend towards signiﬁcant difference (po0.10) between placebo and THC.
fearful faces happy faces control
Figure 1 Schematic outline of the task used to assess effects of THC on processing of facial expressions of emotion. The task
consists of two experimental conditions (fearful faces (left) and happy faces (middle), respectively), during which subjects viewed a
trio of unfamiliar faces and selected one of the two bottom faces that expressed the same facial emotion as the target face on top.
Experimental conditions were interspersed with a sensorimotor control condition (right), during which subjects viewed a trio of
simple geometric shapes (circles, vertical and horizontal ellipses) and selected one of the two bottom shapes identical to the target
shape on top. Each block consisted of four different trios of images presented sequentially for 5 s each. See for detailed information
the experimental procedures section.
M.G. Bossong et al.1690registration purposes. A T1-weighted structural image was obtained
for anatomical registration (parameters: TR 9.5 ms; TE 4.7 ms; ﬂip
angle=81; FOV 220.8 240 159.6; matrix 368 400 266; voxel
size 0.6 mm isotropic, 266 slices (sagittal orientation)).2.6. Functional MRI analysis
Functional MRI data were preprocessed and analyzed using SPM5
(Wellcome Trust Centre for Neuroimaging, London, UK). Preproces-
sing included realignment of functional images, co-registration with
the anatomical volume using the ﬂip angle of 271 volume, spatial
normalization into standard MNI space, and smoothing (FWHM=8
mm), as described previously (van Hell et al., 2011; Bossong et al.,
2012a; Bossong et al., 2012b). There were no signiﬁcant differences
between sessions in scan quality in terms of the average standard
deviation of time series.
First level single subject analysis included a general linear model
regression analysis using a factor matrix with factors for the FF and
HF condition, as well as the instructions that were presented during
the task and factors to correct for slow drifts in the signal up to
0.006 Hz. Group activity maps were created for both the placebo
and THC condition for the contrasts FF–CT and HF–CT.
We chose to perform ROI analyses, because we expected regions
involved in emotional processing to act as a connected network. In
addition, this analysis (unlike voxel-wise whole brain analysis)
allows for both calculation and presentation of effect sizes andfollow-up analysis, and has sufﬁcient power for smaller samples
(Friston et al., 2006; Zandbelt et al., 2008). We preselected ‘task’
voxels that showed a signiﬁcant signal increase associated with the
experimental paradigm (thresholded at t44.1, po0.001). To pre-
vent session bias in voxel selection, voxels were included if they
exceeded threshold in at least one of the four group activity
maps. Regions of interest (ROIs) were identiﬁed by clustering
groups of at least 10 neighboring active voxels (640 mm3). We
chose a lenient threshold for voxel selection to ensure that we
included most regions showing signal changes related to the task.
Notably, the threshold for voxel selection is not related to the
tested experimental hypotheses (Friston et al., 2006). Mean signal
change for each ROI, each subject, and each session (placebo and
THC) was based on regression coefﬁcients (b values) averaged over
voxels in each ROI, extracted using the Marsbar SPM tool (Brett
et al., 2002).
It is at this stage that statistical hypothesis testing was con-
ducted, using SPSS 17. Effects of THC on brain activity were
determined using a repeated measures MANOVA over all 12 ROIs
with drug (two levels: placebo and THC), condition (two levels:
FF–CTand HF–CT) and ROI (12 levels: all regions included) as within-
subjects factors. Follow up analyses were performed for separate
ROIs with factors drug (two levels: placebo and THC) and condition
(two levels: FF–CT and HF–CT). Post hoc paired t tests were
performed to further investigate effects of THC on individual task
conditions. ROI analyses are presented as a further descriptive
exploration of the main hypothesis test, and are, as such, not
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Figure 2 Task performance. (a) Performance accuracy as mean percentage of correctly identiﬁed targets after placebo and THC
administration. (b) Reaction times of correct responses after placebo and THC administration (n=11; mean7SEM). * Signiﬁcant
difference between placebo and THC (po0.05). ms, milliseconds.
1691Endocannabinoid system in emotional processingcorrected for multiple comparisons if the omnibus network test
proves to be signiﬁcant.2.7. Correlations
To assess relationships between effects of THC on anxiety levels,
performance accuracy (FF and HF condition) and network activity
(FF and HF condition), correlation analyses were performed using
Pearson's correlation coefﬁcient (THC vs. placebo, two-sided).3. Results
3.1. Drug levels and behavioral measurements
Plasma concentrations of THC and its main metabolites
were 82.3745.9 ng/ml (THC), 4.475.5 ng/ml (11-nor-9-
carboxy-THC) and 2.671.3 ng/ml (11-OH-THC), 5 min after
inhalation of 6 mg THC.
Analysis of subjective effects before and after perfor-
mance of the emotional faces task revealed a signiﬁcant
THC-induced increase in VAS score of ‘feeling high’ (F(1,10)
=11.06, p=0.008), ‘internal perception’ (reﬂecting inner
feelings that do not correspond with reality) (F(1,10)=6.21,
p=0.032), and ‘external perception’ (reﬂecting mispercep-
tion of external stimuli or changes in the awareness of the
environment) (F(1,10)=11.97, p=0.006) compared to pla-
cebo. In addition, THC signiﬁcantly reduced ‘alertness’
(F(1,10)=8.19, p=0.017), ‘contentedness’ (F(1,10)=6.96,
p=0.025), and ‘calmness’ (F(1,10)=7.72, p=0.020). THC
caused a trend towards a signiﬁcant increase in VAS score of
‘anxiety’ (F(1,10)=3.60, p=0.087). Subjective effects are
summarized in Table 2.
Heart rate increased signiﬁcantly after THC compared
with placebo (16.0713.9 and 1.579.9 bpm increase com-
pared to baseline, respectively; po0.001). For a more
detailed description of drug levels and behavioral measure-
ments following THC see van Hell et al. (2011).3.2. Task performance
The effect of THC administration on performance accuracy
was signiﬁcantly different between the two experimental
conditions (drug condition, F(1,10)=7.11; p=0.024), with
a THC-induced decrease in the mean percentage of cor-
rectly identiﬁed emotions for FF only (from 99.471.9% to
93.877.4%, p=0.024). Reaction times differed signiﬁcantly
between conditions (condition, F(1,10)=17.53; p=0.002),
with the longest response time for FF, but showed no effects
of THC administration (drug, F(1,10)=2.59; p=0.139)
(Figure 2).
3.3. Selection of regions of interest
Processing of facial expressions of emotion (pooled FF–CT
and HF–CT group activity maps) yielded a network of 12
brain regions, comprising vermis, bilateral prefrontal cor-
tex, hippocampus and occipital cortex, and right amygdala/
parahippocampal gyrus, inferior orbital frontal gyrus, sup-
plementary motor area, superior parietal gyrus and middle
frontal gyrus (Table 3 and Figure 3).
3.4. Brain activity
Brain activity in the network of ROIs showed a signiﬁcant
interaction effect between drug and condition (F(1,10)
=6.66; p=0.027), indicating that THC administration had
a different effect on the processing of FF and HF. There was
no signiﬁcant effect of drug (F(1,10)=0.14, p=0.718) or
condition (F(1,10)=2.71, p=0.131), and no difference in
the effect of THC between ROIs (drug conditionROI
interaction, F(6,64)= 1.69, p=0.133). Post hoc analysis
revealed a signiﬁcant THC-induced decrease in FF activity
(from 0.7070.05 to 0.5170.06, p=0.017). This suggests
that the signiﬁcant interaction effect between drug and
condition is mainly reﬂected in decreased processing of FF
(Table 3 and Figure 4).
Table 3 Effects of Δ9-tetrahydrocannabinol (THC) on brain activity related to matching of facial expressions of emotion
(n=11).
ROI Activated brain region Cluster size
(mm3)
MANOVA effects (F(1,10)) Condition effects
Drug Condition Drugncondition Fearful
faces
Happy
faces
Network 155,704 0.14,
p=0.718
2.71,
p=0.131
6.66,
p=0.027n
p=0.017n p=0.285
1 Vermis 832 0.40,
p=0.544
1.92,
p=0.196
13.70,
p=0.004n
p=0.066 p=0.454
2 Occipital cortex L 59,064 0.56,
p=0.472
1.91,
p=0.197
10.12,
p=0.010n
p=0.015n p=0.179
3 Occipital cortex R 74,496 1.14,
p=0.312
1.72,
p=0.218
5.79,
p=0.037n
p=0.026n p=0.540
4 Amygdala / Parahippocampal
gyrus R
896 0.84,
p=0.382
0.01,
p=0.910
0.14, p=0.716 p=0.716 p=0.133
5 Inferior orbital frontal gyrus R 2944 2.93,
p=0.118
0.49,
p=0.500
3.18, p=0.105 p=0.636 p=0.024n
6 Hippocampus L 1728 0.16,
p=0.698
1.41,
p=0.263
8.06,
p=0.018n
p=0.128 p=0.280
7 Hippocampus R 2176 3.46,
p=0.092
1.16,
p=0.307
2.87, p=0.121 p=0.022n p=0.946
8 Prefrontal cortex L 1536 0.55,
p=0.477
6.05,
p=0.034n
4.64, p=0.057 p=0.032n p=0.349
9 Prefrontal cortex R 8384 0.01,
p=0.932
2.92,
p=0.118
5.26,
p=0.045n
p=0.281 p=0.195
10 Superior parietal gyrus R 1408 2.47,
p=0.147
1.33,
p=0.276
7.94,
p=0.018n
p=0.012n p=0.413
11 Middle frontal gyrus R 960 2.56,
p=0.141
2.87,
p=0.121
2.69, p=0.132 p=0.110 p=0.544
12 Supplementary motor area R 1280 4.09,
p=0.071
0.63 p=0.447 6.52,
p=0.029n
p=0.522 p=0.001n
Group activity maps for placebo and THC were thresholded at t44.1, po0.001, cluster size Z10 voxels (640 mm3). Overall effects
were determined with repeated measures MANOVA, with drug and condition as factors. Condition effects were assessed with
paired t tests. ROI numbers correspond to those shown in Figure 3. ROI, region of interest; L, left; R, right.
nSigniﬁcant effect (po0.05).
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Figure 3 Regions of interest (ROIs) used to assess effects of THC administration on brain activity. ROIs are deﬁned in group activity
maps that were pooled for the placebo and THC condition of both the contrasts FF–CT and HF–CT (n=11; t44.1, po0.001,
uncorrected for multiple comparisons, clusters Z10 voxels). Numbers above slices indicate MNI z coordinates. ROI numbers
correspond to those shown in Table 3. L, left; R, right.
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1693Endocannabinoid system in emotional processingAnalysis of individual ROIs showed a signiﬁcant interac-
tion effect between drug and condition in the vermis
(F(1,10)=13.70; p=0.004), left occipital cortex (F(1,10)
=10.12; p=0.010), right occipital cortex (F(1,10)=5.79;
p=0.037), left hippocampus (F(1,10)=8.06; p=0.018), right
prefrontal cortex (F(1,10)=5.26; p=0.045), right superior
parietal gyrus (F(1,10)=7.94; p=0.018), and right supple-
mentary motor area (F(1,10)=6.52; p=0.029), while there
was a trend in left prefrontal cortex (F(1,10)=4.64,
p=0.057) (not corrected for multiple comparisons). A
signiﬁcant effect of condition was demonstrated in the left
prefrontal cortex (F(1,10)=6.05; p=0.034), but no signiﬁ-
cant drug effects were shown in individual ROIs. ROI results
are summarized in Table 3 and Figure 5.
3.5. Correlations
Anxiety levels showed a signiﬁcant negative correlation with
both FF and HF performance accuracy (r=0.79, p=0.004
and r=0.74, p=0.009, respectively), but not network
activity (r=0.44, p=0.179 and r=0.14, p=0.677). Task per-
formance was not signiﬁcantly correlated with network0
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Figure 4 Activity in the network of ROIs during matching of ‘fea
activity after placebo and THC administration (mean7SEM). (b) Ne
for individual subjects. * Signiﬁcant difference between placebo anactivity (r=0.24, p=0.482 and r=0.25, p=0.461 for FF
and HF, respectively), suggesting that effects of THC on
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showed task-related activity. For the occipital and parietal
regions this effect was predominantly a result of reduced
activity for negative stimuli, while for the supplementary
motor area the effect was mainly reﬂected in higher activity
for positive stimuli. For the right prefrontal cortex, left
hippocampus, and vermis, the effect was only present as an
interaction.
These results suggest that administration of THC shifts the
brain's bias for stimuli that have a negative impact towards a
bias for stimuli that have a positive impact. Our ﬁndings
support the hypothesis of involvement of the eCB system in
modulation of emotional processing. It adds important human
neuroimaging evidence to a large body of literature that
implicates the eCB system in modulation of emotional
responses, as it is the ﬁrst neuroimaging study that shows
network-wide opposite effects of THC for processing stimuli
with a negative and positive emotional content.
Two previous neuroimaging studies are closely related to
the present study. First, this study is in part a reproduction
of that of Phan et al. (2008), with the important notion that
we examined effects of THC in a network of brain regions,
while Phan and colleagues limited their results to the
amygdala. Phan et al. reported reduced amygdala reactivity
for processing of stimuli with a negative emotional content.
Although we did not reproduce this signiﬁcant effect in the
amygdala, we did ﬁnd similar effects in many other regions
involved in processing of emotions. In addition, we detecteda decrease in task performance for matching negative
stimuli, which was consistent with the neuroimaging results.
A second study that is directly relevant to ours is that of
Fusar-Poli et al. (2009). After THC administration, they
demonstrated increased activity in precuneus and primary
motor cortex, and reduced activity in bilateral middle
frontal gyrus and posterior cingulate cortex, together with
subjective anxiogenic effects. Effects of THC on task
performance were not detected. Possibly, differences in
results between our study and Fusar-Poli et al. (2009) are
related to the nature of the fMRI task. In contrast to the
task used in both the present study and that of Phan et al.
(2008), Fusar-Poli and colleagues used a gender discrimina-
tion task, which did not require explicit processing of the
emotional content of the stimuli.
Our results are in line with accumulating evidence for
involvement of the eCB system in modulation of emotional
processing. Animal studies have previously shown reduced
anxiety-like behavior after administration of either low
doses of exogenous cannabinoid agonists including THC or
drugs that enhance levels of endogenous cannabinoids
(Kathuria et al., 2003; Marco et al., 2004; Valjent et al.,
2002; see for a review Hill et al. (2009)). Elimination of
eCB-mediated synaptic transmission through genetic dele-
tion or pharmacological blockade of cannabinoid receptors
produces anxiety- or depressive-like states in animals
(Griebel et al., 2005; Martin et al., 2002; see for a review
Lafenetre et al. (2007)). Human neuropsychological studies
1695Endocannabinoid system in emotional processinghave indicated that THC administration reduces perception
of fearful facial emotions in healthy volunteers (Ballard
et al., 2012), while both acute and long-term administration
of the eCB antagonist rimonabant have been shown to
induce a bias away from positive emotions on a memory
recognition task (Horder et al., 2009, 2012). A recent
neuroimaging study demonstrated that people with a
genetic proﬁle associated with increased eCB signaling
(carriers of FAAH385A) have decreased fear-related amyg-
dala reactivity (Hariri et al., 2009). Clinical trials testing
rimonabant and the inverse agonist taranabant for treat-
ment of obesity have shown depressed mood and anxiety as
the most common adverse events (Addy et al., 2008;
Christensen et al., 2007). Also in humans, the administra-
tion of cannabidiol has been reported to reduce activity in
amygdala, anterior and posterior cingulate cortex during
processing of intensely fearful faces, while the level of
suppression in these regions was correlated with physiolo-
gical markers of anxiety (Fusar-Poli et al., 2009).
The current study also adds arguments for a possible role
of the eCB system in abnormal emotional processing related
to psychiatric disorders, as has been suggested previously
(Ashton and Moore, 2011; Hill et al., 2009). For example,
individuals diagnosed with major depressive disorder exhibit
an attentional bias towards negative cues and a bias away
from positive cues (Surguladze et al., 2004), together with
an increased reactivity towards negative and reduced
reactivity towards positive emotions (Fu et al., 2007;
Surguladze et al., 2005). Administration of antidepressant
medication reduces this bias in patients (Fu et al., 2007;
Harmer et al., 2009), and appears to induce a shift in
emotional bias in healthy volunteers similar to the one
related to THC in the current study (Harmer et al., 2006;
Murphy et al., 2009). Thus, a defect in endocannabinoid
neurotransmission could contribute to the abnormal emo-
tional reactions as seen in patients with a major depression.
This also suggests potential for eCB-mediated medication in
the treatment of psychiatric symptoms related to abnormal
emotional responses.
A potential mechanism underlying the effects of THC
administration on brain activity may be found in the
regulatory role of the eCB system in neurotransmitter
release. The eCB system is a retrograde messenger system
that regulates both excitatory glutamate and inhibitory
GABA neurotransmission according to an ‘on-demand’ prin-
ciple: endocannabinoids are released when and where they
are needed (Heifets and Castillo, 2009). This eCB-mediated
regulation of synaptic transmission is a widespread phenom-
enon in the brain, and is thought to play an important role
in higher brain functions, including emotional processing
(Heifets and Castillo, 2009; Hill et al., 2009). As emotional
responses such as anxiety and fear are associated with
increased glutamate and diminished GABA neurotransmis-
sion (Millan, 2003), the reduced negative emotional bias as
demonstrated in the current study may be the result of a
THC-induced reinstatement of the balance between both
neurotransmitter systems (Ruehle et al., 2012).
THC plasma concentrations and reported subjective
effects in our study indicate that a moderate high dose of
THC was used (Huestis et al., 1992; Ramaekers et al., 2006).
In line with behavioral animal studies that used high doses
of THC (Marco et al., 2004; Valjent et al., 2002), subjectiveratings in the present study are more in the direction of
anxiety-like effects, with a trend towards a signiﬁcant THC-
induced increase in the VAS score of ‘anxiety’, and sig-
niﬁcantly reduced measures of ‘contentedness’ and ‘calm-
ness’. These behavioral ﬁndings seem to contradict the
effects of THC on brain activity. The circumstances of the
experiment, particularly the unfamiliar environment and
the fact that subjects were aware that they had to perform
a task while possibly under the inﬂuence of THC, are likely
to have caused an increase in self-reported feelings of
anxiety. Another possibility may be that self-reported sub-
jective states related to THC may not always be reﬂected in
brain activity related to emotional processing.
Some limitations have to be taken into account in
interpreting the results of this study. First, the sample size
of the current study was small. We therefore cannot
exclude the possibility that subtle effects of THC on brain
activity have been missed. However, the sample is large
enough to detect effects on brain activity with an ROI
approach (Zandbelt et al., 2008). Second, inclusion of
incidental cannabis users, as opposed to non-users, may
affect interpretation of results as previous cannabis use may
inﬂuence the eCB system. The choice for incidental canna-
bis users was based on ethical grounds (van Hell et al.,
2011). Third, although the study was designed to be double-
blind, THC induced behavioral effects that were identiﬁed
by most subjects, possibly causing expectancy effects across
sessions. The inﬂuence of expectancy was minimized by
using a randomized crossover design, thus balancing the
effects of expectancy across study days. Still, it cannot be
excluded that expectancy effects may have affected our
results to some extent. Finally, nonspeciﬁc THC-induced
changes on cerebral blood ﬂow may have confounded our
results (Iannetti and Wise, 2007). However, we have
designed our study to minimize the inﬂuence of this
effect by comparing brain activity between task-speciﬁc
conditions and a control condition, as the nonspeciﬁc
effects of THC on blood ﬂow can be expected to be
present in all conditions. Furthermore, as we found
signiﬁcant differences in THC effects between task con-
ditions, it is unlikely that our ﬁndings are associated with
nonspeciﬁc effects.
We did not ﬁnd signiﬁcant effects of THC on amygdala
activity. Possibly, the subjective anxiety-like effects of THC
administration may have speciﬁcally masked THC-induced
effects on the response of the amygdala, as it has been
shown that particularly amygdala activity may be involved
in the subjective response to pharmacologically induced
anxiety (Eser et al., 2009). This view is supported by results
of Fusar-Poli et al. (2009), who showed strong subjective
anxiety-like effects of THC, but no signiﬁcant effects of THC
administration on the amygdala response.
In conclusion, our study shows that THC administration
induced a network-wide shift from a bias for negative emo-
tional content towards a bias for positive emotional content.
This was accompanied by a reduced ability to recognize
stimuli with a negative emotional content. These ﬁndings
add to existing evidence that implicate the endocannabinoid
system in modulation of emotional reactions, and support a
previously suggested role for the endocannabinoid system in
abnormal emotional processing associated with various
psychiatric disorders.
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